Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of NLRP3 polyclonal antibody
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Goat |
| Applications | ELISA |
More info about NLRP3 polyclonal antibody
| Brand: | Abnova |
| Reference: | PAB6297 |
| Product name: | NLRP3 polyclonal antibody |
| Product description: | Goat polyclonal antibody raised against synthetic peptide of NLRP3. |
| Gene id: | 114548 |
| Gene name: | NLRP3 |
| Gene alias: | AGTAVPRL|AII|AII/AVP|AVP|C1orf7|CIAS1|CLR1.1|FCAS|FCU|FLJ95925|MWS|NALP3|PYPAF1 |
| Gene description: | NLR family, pyrin domain containing 3 |
| Immunogen: | A synthetic peptide corresponding to human NLRP3. |
| Immunogen sequence/protein sequence: | C-EKPELTVVFEPSW |
| Protein accession: | NP_004886 |
| Form: | Liquid |
| Concentration: | 0.5 mg/mL |
| Recommend dilutions: | ELISA (1:32000) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In Tris saline, pH 7.3 (0.5% BSA, 0.02% sodium azide) |
| Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Goat |
| Antigen species / target species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Shipping condition: | Dry Ice |
| Publications: | Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Nat Genet. 2001 Nov;29(3):301-5. |